PT  - JOURNAL ARTICLE
AU  - Xu, Jingsi
AU  - Carruthers, Jonathan
AU  - Finnie, Thomas
AU  - Hall, Ian
TI  - Simplified Within Host and Dose-response models of SARS-CoV-2
AID  - 10.1101/2022.09.20.22279832
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.09.20.22279832
4099  - http://medrxiv.org/content/early/2022/09/22/2022.09.20.22279832.short
4100  - http://medrxiv.org/content/early/2022/09/22/2022.09.20.22279832.full
AB  - Understanding the mechanistic dynamics of transmission is key to designing more targeted and effective interventions to limit the spread of infectious diseases. A well-described within-host model allows explicit simulation of how infectiousness changes over time at an individual level. This can then be coupled with dose-response models to investigate the impact of timing on transmission. We collected and compared a range of within-host models used in previous studies and identified a minimally-complex model that provides suitable within-host dynamics while keeping a reduced number of parameters to allow inference and limit unidentifiability issues. Furthermore, non-dimensionalised models were developed to further overcome the uncertainty in estimates of the size of the susceptible cell population, a common problem in many of these approaches. We will discuss these models, and their fit to data from the human challenge study (see Killingley et al. (2022)) for SARS-CoV-2 and the model selection results, which has been performed using ABC-SMC. The parameter posteriors have then used to simulate viral-load based infectiousness profiles via a range of dose-response models, which illustrate the large variability of the periods of infection window observed for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis report and the research it describes were funded by the PROTECT COVID-19 National Core Study on transmission and environment, which is managed by the Health and Safety Executive (HSE) on behalf of HM Government. Its contents, including any opinions and/or conclusions expressed, are those of the authors alone and do not necessarily reflect UK Government or HSE policy.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://www.nature.com/articles/s41591-022-01780-9 https://www.nature.com/articles/s41591-022-01780-9